China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
MENLO PARK, Calif., March 02, 2017 -- Geron Corporation (Nasdaq:GERN) today announced an abstract submitted by Janssen Research & Development, LLC describing non-clinical data on imetelstat has been accepted for presentation as a poster at the 2017 American Association for Cancer Research (AACR) Annual Meeting to be held in Washington, D.C. from April 1-5, 2017. The abstract is available on the AACR website at www.aacr.org.
Abstract Title: Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax enhances apoptosis in vitro and increases survival in vivo in acute myeloid leukemia (Abstract #1101)
| AACR Session Title: | Combination Therapy 1 | |||
| Session Date: | Monday, April 3, 2017 | |||
| Session Time: | 8:00 a.m. ET - 12:00 p.m. ET |
In accordance with AACR policies, abstracts submitted to the AACR Annual Meeting are embargoed from the time of submission. To be eligible for presentation at the AACR Annual Meeting, information contained in the abstract, as well as additional data and information to be presented at the Annual Meeting, may not be made public before the abstract has been presented in connection with the AACR Annual Meeting.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
